The targeted delivery of bioactive molecules to the appropriate site of action, one of the critical focuses of pharmaceutical research, improves therapeutic outcomes and increases safety at the same time; a concept envisaged by Ehrlich over 100 years ago when he described the "magic bullet" model. In the following decades, a considerable amount of research effort combined with enormous investment has carried selective drug targeting into clinical practice via the advent of monoclonal antibodies (mAbs) and antibody-drug conjugates derivatives. Additionally, a deeper understanding of physiopathological conditions of disease has permitted the tailored design of targeted drug delivery platforms that carry drugs, many copies of the same drug, and different drugs in combination to the appropriate site of action least selectively or preferentially. The acquired know-how has provided the field with the design rationale to develop a successful delivery system that will provide new and improved means to treat many intractable diseases and disorders. In this review, we discuss a wide range of molecular platforms for drug delivery, and focus on those with more success in the clinic, given their potential for targeted therapies.

中文翻译：

---

用于靶向药物递送的分子平台。

将生物活性分子靶向递送至适当的作用部位，这是药物研究的关键重点之一，可改善治疗效果并同时提高安全性；埃里希（Ehrlich）在100多年前描述“魔术子弹”模型时就设想了这一概念。在随后的几十年中，大量的研究工作与巨大的投资相结合，通过单克隆抗体（mAbs）和抗体-药物偶联物衍生物的问世将选择性药物靶向应用于临床实践。此外，对疾病的生理病理状况的更深入了解使得可以针对性地设计针对性的药物输送平台，该平台可以承载药物，许多相同药物的副本，以及将不同药物组合到适当的作用位点上，至少是选择性或优先选择的。获得的专业知识为该领域提供了开发成功的输送系统的设计依据，该系统将为治疗许多难治性疾病和障碍提供新的改良手段。在这篇综述中，我们讨论了广泛的药物输送分子平台，并着眼于在临床上取得更大成功的分子平台，因为它们具有靶向治疗的潜力。